Dignity reports Phase II atopic dermatitis data

Dignity Sciences Ltd. (Dublin, Ireland) said 0.1%, 1% and 5% topical DS107E dose-dependently and significantly improved modified Eczema Area and Severity Index (mEASI) scores, the primary endpoint, at...